Milner Therapeutics Institute and LifeArc extend strategic partnership

Combines LifeArc’s translational expertise with the Milner’s cutting-edge bioinformatics

New £30 million translational partnership will accelerate development of new treatments for people with dementia

Funding will accelerate development of new diagnostic tests, treatments, and devices for people with dementia.

Promising new asthma medicine ready to enter early clinical trials

LifeArc scientists instrumental to the development of the world’s first anti-IL17BR antibody, now being trialled as a treatment for severe asthma

Pandemic Science Hub to develop better drugs to fight lung disease

New, multi-million pound research programme at the University of Edinburgh will develop treatments for lung infections

Action Medical Research and LifeArc announce another round of funding to support translational research into children’s rare diseases

£1m fund to progress promising translational research addressing a medical need for children and young people

LifeArc co-founded company RQ Bio signs licensing agreement with AstraZeneca worth up to $157m plus royalties for monoclonal antibodies against SARS-CoV-2

AstraZeneca granted exclusive worldwide licence to develop, manufacture and commercialise RQ Bio’s existing early-stage monoclonal antibodies (mAbs)…

Accelerating progress against dementia 

How can we reduce the impact of dementia on individuals, families and wider society?

Learning from translational research success stories during the COVID-19 pandemic

Melanie Lee on how bringing together diverse teams united under a clear purpose can deliver extraordinary results.

Hackathon brings scientists together to tackle brain health

Together with the patient charity Motor Neurone Disease (MND) Association, LifeArc co-sponsored an MND challenge within a…